Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.
OBJECTIVES: To determine the safety, pharmacokinetics, and activity of an anti-tumor necrosis factor (TNF)-alpha monoclonal antibody in severe sepsis. DESIGN: Open-label, prospective, phase II multicenter trial with escalating doses of a murine monoclonal antibody (CB0006). SETTING: Twelve academic...
Main Authors: | Fisher, C, Opal, S, Dhainaut, J, Stephens, S, Zimmerman, J, Nightingale, P, Harris, S, Schein, R, Panacek, E, Vincent, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
1993
|
Similar Items
-
Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
by: Fisher, C, et al.
Published: (1994) -
Expression of Serum Cytokines Profile in Neonatal Sepsis
by: Chen S, et al.
Published: (2022-06-01) -
Recent Advances in Monoclonal Antibody-Based Approaches in the Management of Bacterial Sepsis
by: Kusum Kharga, et al.
Published: (2023-03-01) -
A Comparative Review of Cytokines and Cytokine Targeting in Sepsis: From Humans to Horses
by: Kallie J. Hobbs, et al.
Published: (2024-09-01) -
Antibody-modified conduits for extracorporeal selective cytokine filtration in sepsis
by: Moroi, Morgan K
Published: (2016)